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ABSTRACT
The present study was designed to investigate the effect of
metformin on the impairment of intermediate-conductance and
small-conductance Ca21-activated potassium channels (IKCa and
SKCa)–mediated relaxation in diabetes and the underlying mecha-
nism. The endothelial vasodilatation function of mesenteric arteries
was assessed with the use of wire myography. Expression
levels of IKCa and SKCa and phosphorylated Thr
172 of AMP-
activated protein kinase (AMPK) were measured using Western
blot technology. The channel activity was observed using a
whole-cell patch voltage clamp. Reactive oxygen species (ROS)
weremeasured using dihydroethidium and 29,79-dichlorofluorescein
diacetate. Metformin restored the impairment of IKCa- and SKCa-
mediated vasodilatation in mesenteric arteries from streptozotocin-
induced type 2 diabetic rats and that from normal rats incubated
with advanced glycation end products (AGEs) for 3 hours. In cultured
human umbilical vein endothelial cells (HUVECs), 1 mM metformin
reversed AGE-induced increase of ROS and attenuated AGE-
and H2O2- induced downregulation of IKCa and SKCa after long-
term incubation (.24 hours). Short-term treatment (3 hours) with
1 mMmetformin reversed the decrease of IKCa and SKCa currents
induced by AGE incubation for 3 hours without changing the
channel expression or the AMPK activation in HUVECs. These
results are the first to demonstrate that metformin restored
IKCa- and SKCa-mediated vasodilatation impaired by AGEs in rat
mesenteric artery, in which the upregulation of channel activity
and protein expression is likely involved.
Introduction
Vascular diseases are the principal causes of morbidity and
mortality in patients with diabetes mellitus. Loss of the mod-
ulatory role of the endothelium may be a critical and initiating
factor in the development of diabetic vascular diseases (Hartge
et al., 2006; Vlassara et al., 2008; Vanhoutte et al., 2009).
Endothelium-dependent vasodilatation is an accessible parameter
to probe endothelial function in different pathophysiological
conditions. The endothelium-mediated dilation of arteries can
be achieved by the release of relaxing factors, such as nitric oxide
(NO), prostacyclin, and endothelium-derived hyperpolarizing
factor (EDHF), from the endothelial cells. Findings from arteries
of many species, including humans, indicate that endothelial
intermediate-conductance Ca21-activated potassium channels
(IKCa) and small-conductance Ca
21-activated potassium chan-
nels (SKCa) play a pivotal role in mediating the EDHF effects in
many small vascular beds (Busse et al., 2002; Dora et al., 2008;
Félétou and Vanhoutte, 2009; Grgic et al., 2009). Studies
indicate that the main IKCa isoform is the KCa3.1 subunit, and
the SKCa isoform is KCa2.3 in endothelial cells (Eichler et al.,
2003). In vivo studies in mice show that deficiency of KCa2.3
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and/or KCa3.1 channels (Taylor et al., 2003; Si et al., 2006;
Brähler et al., 2009) leads to elevated blood pressure. In ad-
dition, opening KCa2.3 andKCa3.1 channels decreasesmyogenic
tone and increases acetylcholine (ACh)-induced relaxation in
rat cremaster arterioles (Sheng et al., 2009). It has been
reported that IKCa- and SKCa-mediated relaxation is impaired
in resistance arteries of diabetic rats, which is related to the
downregulation of these channels (Wigg et al., 2001; Burnham
et al., 2006; Leo et al., 2011).
Advanced glycation endproducts (AGEs) are aheterogeneous
group of complex compounds that are formed irreversibly in
serum and tissues via a chain of nonenzymatic chemical
reactions (Vlassara et al., 2008). AGEs are thought to impair
endothelium-dependent vasodilatation in diabetes (Gao et al.,
2008; Sena et al., 2012). Our previous study found that AGEs
impaired IKCa- and SKCa-mediated relaxation in rat mesen-
teric arteries via downregulation of KCa3.1 and KCa2.3
channels induced by oxidative stress (Zhao et al., 2014).
Metformin is currently considered the first-line pharmaco-
logical therapy in type 2 diabetes mellitus (T2DM) (Consoli
et al., 2004; Bennett et al., 2011), and showed a greater effect
than sulfonylurea or insulin for any diabetes-related endpoint,
all-cause mortality, and stroke (UK Prospective Diabetes Study
(UKPDS) Group, 1998). Metformin provides more cardiovascu-
lar protection. A significant reduction was also observed re-
garding myocardial infarction at the end of the trial in the
metformin group compared with the conventional group (UK
Prospective Diabetes Study (UKPDS) Group, 1998). Metformin
is associated with improvement in some markers of endothelial
function, which may explain why it is associated with a de-
creased risk of cardiovascular disease in T2DM (de Jager et al.,
2014). Both in vivo and in vitro metformin improved ACh-
induced relaxation in insulin-resistant rats, apparently through
NO-dependent relaxation (Katakam et al., 2000). Metformin
improved the vascular function in obese nondiabetic rats
through reduction of reactive oxygen species (ROS) generation,
modulation of membrane hyperpolarization, correction of the
unbalanced prostanoids release, and increase in the sensitivity
of the smooth muscle to NO (Lobato et al., 2012). But the effect
of metformin on IKCa- and SKCa-mediated vasodilatation in
small arteries impaired by AGEs remains unknown.
In this study, we found that metformin restored IKCa- and
SKCa-mediated vasodilatation impaired by AGEs in rat
mesenteric artery, which was related to the upregulation of
channel activity and protein expression.
Materials and Methods
Animals. Experimental protocols were approved by the Institu-
tional Animal Care and Use Committee of Xi’an Jiaotong University
and conformed with the Guide for the Care and Use of Laboratory
Animals published by the National Institutes of Health. Male
Sprague-Dawley rats (173 6 18 g) were housed under the following
conditions: 226 2°C, humidity of 556 5%, and a 12/12-hour light/dark
cycle. They were randomly divided into control animals (n 5 6) and
diabetic animals (n 5 14). Diabetes was induced by a single in-
traperitoneal injection of 30mg·kg21 streptozotocin (STZ) after 8 weeks
on a modified high-fat and high-glucose diet (10% grease, 20% sucrose,
1% bile salt, and 2.5% cholesterol) (Wang et al., 2010; Su et al., 2011).
Blood glucose was measured using a One Touch Sure Step Glucose
Meter (LifeScan Inc., Milpitas, CA) 1 week after STZ injection. Animals
with.11.1mmol·l21 blood glucose (n5 12) were randomly divided into
the diabetesmellitus (DM) group (n5 6) and themetformin group (n5 6).
Animals in the DM and metformin groups were fed a high-fat and
high-glucose diet for another 4 weeks after STZ injection, then
a standard rat chow for an additional 2 months. Rats in themetformin
group were treated with metformin (300 mg·kg21·d21 intragastric
administration) after their blood glucose increased for 3 months.
Control animals were fed the standard rat chow and injected with the
drug vehicle citric acid buffer.
Preparation of Advanced Glycation End Product–Bovine
Serum Albumin. Advanced glycation end product–bovine serum
albumin (AGE-BSA) was prepared as described previously (Zhao
et al., 2012). In brief, BSAwith low endotoxin was dissolved in 0.5 mM
phosphate-buffered saline (PBS; pH 7.4) containing 1.6 mM
D-glucose, sterilized by ultrafiltration, and then incubated at 37°C
for 12 weeks, followed by dialysis against PBS for 24 hours to remove
unincorporated glucose. Control nonglycated BSA was prepared with
the same procedure without D-glucose inclusion. AGE-BSA content
was estimated by fluorescence spectroscopy (excitation at 390 nm and
emission at 460 nm) at a protein concentration of 1 mg·ml21, which
indicated a 10-fold increase in fluorescence in AGE-BSA compared
with control BSA. The prepared AGE-BSA and unmodified BSA were
sterilized by ultrafiltration, respectively, and stored at 220°C until
use. Endotoxin levels of each preparation were measured by limulus
amebocyte lysate assay (E-Toxate; Sigma-Aldrich, St. Louis, MO) and
were found to be ,0.8 EU·ml21.
Isometric ForceMeasurements inMesenteric Small Arteries.
After the rats were anesthetized with sodium pentobarbital
(50 mg·kg21, i.p.), the mesenteric arcade was isolated and immedi-
ately placed in ice-cold Krebs-Henseleit solution (KHS; pH 7.4) gassed
with amixture of 95%O2 and 5% CO2. The composition of KHS was as
follows (in mM): NaCl 115, NaHCO3 25, KCl 4.6, NaH2PO4 1.2, MgCl2
1.2, CaCl2 2.5, and glucose 10.0. The third-order branches of the
superior mesenteric artery (internal diameter ∼300 mm) were iso-
lated, cleared of fat and connective tissue, and cut into 2-mm-long
rings. The arterial rings were threaded onto two stainless steel wires
(40 mm in diameter) and were mounted in 5-ml chambers of a
multimyograph system (model 610M; Danish Myo Technology,
Aarhus, Denmark) containing KHS continuously aerated with 95%
O2 and 5% CO2 at 37°C for isometric force measurements. Tension
signals were relayed to a PowerLab recording unit (ADInstruments
Ltd., Aarhus, Denmark) and saved to Chart 7 for Windows software
(ADInstruments Ltd.). After being mounted, the arteries were
allowed to equilibrate for 20 minutes before normalization. The
passive tension–internal circumference was determined by stretching
to 90% of L100, where L100 is defined as the circumference of the
relaxed artery exposed to a transmural pressure of 100 mm Hg, as
previously described by McPherson (1992). The vessels of rats in the
control, DM, and metformin groups were then allowed to equilibrate
for at least 60 minutes, and with the bath solution changed every
15 minutes. After the equilibration, reactivity of the rings was
checked thrice by administration of 60-mM KCl (achieved by sub-
stitution of NaCl in KHS with an equimolar concentration of KCl). To
assess the integrity of the endothelium, mesenteric arteries were
precontracted with phenylephrine (PE; 1 mM), and a high dose of ACh
(10 mM) was used to relax the artery rings. ACh-induced relaxation
was greater than 80% of the precontracted tone in all cases, indicating
that the endothelium was functionally intact.
Myograph Protocol. After further washouts, arteries were again
precontracted with 1 mM PE. The effect of the treatment on relaxant
responses was determined by cumulative concentration-response
curves to ACh (0.1 nM to 10 mM) and sodium nitroprusside (SNP;
0.01 nM to 10 mM). In addition, responses to AChwere examined after
15-minute incubation with 100 mM N-nitro-L-arginine (L-NAME),
a nonselective nitric oxide synthase (NOS) inhibitor, and 10 mM
indomethacin (INDO), a blocker of cyclooxygenase (COX). The arteries
were again washed and rested for 30 minutes in KHS before being
incubated with 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-
34; 10 mM), a selective blocker of IKCa, or 6,12,19,20,25,26-hexahydro-
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tetraazacyclotricosine-5,13-diium (UCL-1684; 0.1 mM), a selective
blocker of SKCa, in the continuous presence of INDO and L-NAME,
and the ACh concentration-response curve was repeated. In addition,
the cumulative concentration-response curves to 6,7-dichloro-1H-
indole-2,3-dione 3-oxime (NS309; 0.1 nM to 1 mM), an IKCa and SKCa
opener, of the arteries incubated with or without 10 mM TRAM-34 or
0.1 mM UCL-1684 were also recorded.
In a subset of experiments, the vessels from normal rats underwent
the same process, except that the vessels were equilibrated for 3 hours
in KHS without or with 200 mg·ml21 BSA, 200 mg·ml21 AGE-BSA, or
1 mM metformin (preincubation for 30 minutes) plus 200 mg·ml21
AGE-BSA after normalization. Besides the responses to ACh, the
NS309 (0.1 nM to ∼1 mM) concentration-response curves of the vessels
incubated with or without 10 mMTRAM-34 or 0.1 mMUCL-1684 were
also recorded.
Cell Culture and Treatments. Human umbilical vein endothe-
lial cells (HUVECs) (CRL-1730) were purchased from American Type
Culture Collection (Manassas, VA). Cells were cultured in Dulbecco’s
modified Eagle’s medium/F12 (Gibco, Manassas, VA) containing 10%
fetal bovine serum (Invitrogen, Carlsbad, CA), penicillin (100 U·ml21),
and streptomycin (100 mg·ml21) and incubated at 37°C in a humidified
atmosphere with 5% CO2. The medium was changed twice weekly.
Cells at 80% confluence were starved for 24 hours in Dulbecco’s
modified Eagle’s medium/F12 containing 0.1% fetal bovine serum
before being treated with different interventions.
Western Blot Analysis. HUVECs incubated with a different stim-
ulus were lysed with ice-cold modified RIPA (Radio-Immunoprecipitation
Assay) Lysis Buffer (60 mM Tris-HCl, 0.25% SDS, 1 mM sodium
fluoride, 1 mM sodium orthovanadate, 10 mg·ml21 aprotinin and
leupeptin). The lysates were then centrifuged at 12,000 g for
15 minutes at 4°C. After transferring the supernatant to a fresh ice-
cold tube, the protein concentration was determined with BCA protein
assay. Equal concentrations of proteins were mixed with SDS sample
buffer and denatured at 100°C for 10 minutes. The samples were
separated on an SDS–10% polyacrylamide gel, then transferred to
a PVDF (polyvinylidene difluoride) membrane at 300 mA for 2 hours in
a transfer buffer containing 20 mM Tris, 150 mM glycine, and 20%
methanol. The membranes were blocked with 5% nonfat dried milk in
Tris-buffered saline/Tween 20 (0.1% Tween 20) for 1 hour. After
blocking, the blots were incubated in primary antibody for KCa3.1
(1:300), KCa2.3 (1:200), AMP-activated protein kinase (AMPK) (1:800),
or phosphorylated AMPK (p-AMPK) Thr172 (1:800) at 4°C overnight,
and then incubated with horseradish peroxidase–conjugated secondary
antibodies (1:5000) for 1 hour at room temperature. The bound anti-
bodies were detected with an enhanced chemiluminescence detection
system (Amersham, Piscataway, NJ) and quantified by densitometry
using a Chemigenius Bio-imaging System (Syngene, Cambridge, UK).
Based on the results from our preliminary experiments, we found that
stimulation with 200 mg·ml21 BSA or 200 mg·ml21 AGE-BSA for
48 hours did not affect glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) expression. Therefore, after stripping, the membrane was
then reprobed with a loading control antibody GAPDH (1:5000) to
normalize for the amount of proteins. The ratio of band intensity to
GAPDH was obtained to quantify the relative protein expression level.
Electrophysiology. Membrane current was recorded in cultured
HUVECs with the whole-cell patch-clamp technique as described
previously (Wang et al., 2013;Wu et al., 2013). The detachedHUVECs
were placed into a 0.2-ml cell chamber mounted on an inverted micro-
scope, allowed to settle to the bottom (∼20 minutes), and then super-
fused with Tyrode’s solution (pH 7.4), which contained the following
(mM): 136 NaCl, 5.4 KCl, 1.0 MgCl2, 1.8 CaCl2, 10 glucose, and
10 HEPES. Borosilicate glass electrodes (1.2-mm outer diameter) were
pulled with a Brown-Flaming puller (model P-97; Sutter Instrument
Co., Novato, CA), and had a resistance of 2–3 MV when filled with
pipette solution, which contained the following (mM): 120 K-aspartate,
20 KCl, 1.0 MgCl2, 5.0 EGTA, 5 Na-phosphocreatine, 5 Mg-ATP,
0.1 GTP, 10HEPES, and 500 nM freeCa21with pHadjusted to 7.2with
KOH. The tip potentials were zeroed before the pipette contacted the
cell. After a gigaohm seal was obtained by negative suction, the cell
membrane was ruptured by a gentle suction to establish whole-cell
configuration. Membrane currents were recorded with an EPC-9 patch-
clamp amplifier and Pulse software (Heka Elektronik, Lambrecht,
Germany). Command pulses were generated by a 12-bit digital-to-analog
converter controlled by Pulse software. All current recording experiments
were conducted at room temperature (22–23°C).
Intracellular ROS Detection. Intracellular ROS generation was
measured with the fluorescent probes of dihydroethidium (DHE) and
29,79-dichlorofluorescein diacetate (DCF-DA). HUVECs grown on cover-
slips were stimulated with 200 mg·ml21 BSA, 200 mg·ml21 AGE-BSA, or
200 mg·ml21 AGE-BSA plus 1 mM metformin for 24 hours. Serum-
deprived cells were washed with PBS, loaded with 5 mM DHE or 4 mM
DCF-DA, and incubated for 30 minutes at 37°C. Differential inter-
ference contrast images were obtained using fluorescence microscopy.
Reagents. UCL-1684, TRAM-34, NS309, metformin, BSA, DHE,
DCF-DA, and other chemicals used in this study were obtained from
Sigma-Aldrich. Anti-KCa3.1 and anti-KCa2.3 antibodies were from
Alomone Laboratories Ltd. (Jerusalem, Israel). All drugs were dissolved
in distilled water, with the exception of INDO, NS309, and UCL-1684,
which were dissolved in dimethylsulfoxide.
Statistical Analysis. Results are presented as means 6 S.E.M.,
and n represents the number of animals or the number of assays.
Concentration-response curves from rat isolated mesenteric arteries
were made with Prism version 5.0 software (GraphPad Software, San
Diego, CA) and other figures with SigmaPlot 10.0 software (Systat
Software, San Jose, CA). Percentage values of relaxation to ACh or
SNP were measured as a percentage of precontraction to PE. In this
study, IKCa- and SKCa-mediated relaxation refers to the relaxation
which can be blocked by the selective blockers, UCL-1684 or TRAM-34.
Percentage values of relaxation of IKCa- and SKCa-mediated relaxation
were calculated as the difference in value between the percentage
values of relaxation before and after incubation with 0.1 mMUCL-1684
or 10 mM TRAM-34. Group percentage values of relaxation were
compared via one-way analysis of variance (ANOVA) with Tukey’s post
test, whereas one-way ANOVAwith Bonferroni’s post test was used for
other results. P , 0.05 was considered statistically significant. All
statistical analyses were made with Prism version 5.0 software.
Results
Characteristics of Diabetic Rat Model. Table 1 dis-
plays the characteristics of a diabetic rat model after 3months
receiving STZ or vehicle injection. Compared with control, the
diabetic rats exhibited decreased body weight and increased
blood glucose and glycated hemoglobin (HbA1c) level. Treat-
ment with metformin partly reversed the increasing of blood
glucose and HbA1c level but further decreased the body
weight of diabetic rats.
Influences of Metformin on IKCa- and SKCa-Mediated
Relaxation in Small Arteries from Diabetic Rats. To
examine whether endothelium-dependent relaxation in
small arteries was damaged in diabetic rats, the third-
order mesenteric arteries were isolated and their isometric force
TABLE 1
Body weight, blood glucose, and glycated hemoglobin levels of rats in
control, DM, and metformin groups
Values are the mean 6 S.E.M. and were analyzed by one-way ANOVA with
Bonferroni’s post test (n = 6 rats).
Control DM Metformin
Body weight (g) 515 6 15 351 6 12** 278.3+7.2##
Blood glucose (mM) 6.33 6 1.33 23.13 6 1.36** 13.37 6 6.33##
HbA1c (%) 9.35 6 0.81 18.57 6 0.53** 15.06 6 0.86##
**P , 0.01 versus control rats; ##P , 0.01 versus DM rats.
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to 10210∼1025 M ACh was measured. Figure 1A illustrates
the typical records of concentration-dependent relaxations
induced by ACh in PE-precontracted mesenteric arteries from
control rats, diabetic rats (DM), and metformin-treated
diabetic rats. As shown in Fig. 1C, diabetes significantly
reduced the relaxation in response to ACh in mesenteric
arteries (n 5 6, P , 0.01 vs. control), whereas metformin
treatment restored the adverse condition (n5 6, P, 0.05, P,
0.01 vs. DM). However, the relaxation in response to SNP was
not affected (Fig. 1B). Incubation with 100 mM L-NAME and
10 mM INDO to block NOS and COX depressed the relaxant
response to ACh in arteries from all rats, but the relaxation
still decreased in mesenteric arteries of diabetic rats com-
pared with control rats, and treatment with metformin partly
reversed this decrease (Fig. 1D; n 5 6, P , 0.01 vs. control,
P , 0.01 vs. DM). These results demonstrate that metformin
restored the impaired EDHF-mediated relaxation in small
arteries of diabetic rats.
To determine the role of IKCa and SKCa in impaired EDHF-
type relaxation in diabetes, we examined responses to ACh in
the presence of TRAM-34 (IKCa blocker) or UCL-1684 (SKCa
blocker) in addition to NOS and COX inhibition (L-NAME 1
INDO). Compared with arteries of control rats, IKCa- and
SKCa-mediated relaxation decreased in arteries of DM rats
(Fig. 1, E andG;n5 6,P, 0.01 vs. control).Metformin treatment
partly reversed the decrease of IKCa- and SKCa-mediated
relaxation (Fig. 1, F and H; n 5 6, P , 0.05, P , 0.01 vs. DM).
Effect of Metformin on IKCa- and SKCa-Mediated
Relaxation in Small Arteries Incubated with AGEs. We
then examined the role of metformin in AGE-induced impair-
ment of EDHF-type relaxation in small arteries. The third-
order mesenteric arteries from normal rats were incubated
without or with 200 mg·ml21 BSA, 200 mg·ml21 AGE-BSA, or
1 mM metformin plus 200 mg·ml21 AGE-BSA for 3 hours. BSA
incubation did not affect the response of arteries to ACh, but
AGE-BSA incubation attenuated it. Metformin preincubation
Fig. 1. Effect of metformin on IKCa- and SKCa-mediated ACh-induced relaxation in small arteries of diabetic rats. (A) Typical records showing
concentration-dependent relaxations induced by ACh in PE-precontracted mesenteric arteries from control rats, diabetic rats (DM), and metformin-
treated diabetic rats (dots indicate ACh concentration from 10210 to 1025 M). (B–H) Cumulative concentration-response curves for SNP (B) and ACh in
the absence (C) or presence of L-NAME+INDO (D), L-NAME+INDO+TRAM-34 (E and F), and L-NAME+INDO+UCL-1684 (G and H) in endothelium-
intact mesenteric arteries isolated from control rats, diabetic rats, and metformin-treated diabetic rats. In each group of experiments, mesenteric
arteries were precontracted with 1 mM PE. Results are shown as the mean 6 S.E.M. n = 6 rats, one-way ANOVA with Tukey’s post test. **P , 0.01 vs.
control; #P , 0.05, ##P , 0.01 vs. DM).
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inhibited the adverse effect of AGEs (Fig. 2B; n5 6,P, 0.01 vs.
BSA;P, 0.05,P, 0.01 vs. AGE-BSA). However, the relaxation
in response to SNP was not affected by AGE-BSA incubation
(Fig. 2A). When incubating arteries with L-NAME and INDO,
AGE-BSA also decreased the relaxant response to ACh, and
metformin restored the adverse condition (Fig. 2C; n 5 6, P ,
0.05, P , 0.01 vs. BSA; P , 0.05, P , 0.01 vs. AGE-BSA).
Effects of metformin on AGE-induced impairment of IKCa-
and SKCa-mediated relaxation in the third-order mesenteric
arteries from normal rats were further investigated. As shown
in Fig. 2 (D and G), there was no difference between the
control and BSA groups. Compared with incubation with
BSA, 3-hour incubation with 200 mg·ml21 AGE-BSA reduced
both IKCa- and SKCa-mediated relaxation in response to ACh
(Fig. 2, E and H; n5 6, P, 0.05, P, 0.01 vs. BSA). Metformin
treatment also incompletely reversed this damage (Fig. 2, F and I;
P , 0.05, P , 0.01 vs. AGE-BSA).
To confirm this conclusion, NS309, an opener of both IKCa
and SKCa channels, was then used to induce vasorelaxation in
small arteries. Figure 3 displays the cumulative concentration-
response curves to NS309 in endothelium-intact mesenteric
arteries from normal rats. There was no difference in the
relaxation in response to NS309 between control and BSA-
incubated arteries (Fig. 3, A and D). AGE-BSA incubation
significantly reduced the relaxant response to NS309 in
arteries treated without or with 10 mM TRAM-34 (Fig. 3B;
n 5 6, P , 0.05, P , 0.01 vs. BSA) or 0.1 mM UCL-1684
(Fig. 3E; n 5 6, P , 0.01 vs. BSA). The adverse effects were
partially revived by preincubation with 1 mM metformin
(Fig. 3, C and F; n5 6, P, 0.05, P, 0.01 vs. AGE-BSA). These
results further confirm that metformin restored IKCa- and
SKCa-mediated relaxation in small arteries damaged by AGEs.
Effect of Metformin on IKCa and SKCa Channel
Expression in HUVECs Incubated with AGEs. According
to our previous study, AGEs reduced the expression of KCa3.1
and KCa2.3 channels in dose-dependent and time-dependent
manners (Zhao et al., 2014). We therefore investigated whether
the effect of metformin on IKCa- and SKCa-mediated relaxation
Fig. 2. Effect of metformin on IKCa- and SKCa-mediated ACh-induced relaxation in small arteries incubated with AGEs. (A–I) Cumulative concentration-
response curves for SNP (A) and ACh in the absence (B) or presence of L-NAME+INDO (C), L-NAME+INDO+TRAM-34 (D–F), and L-NAME+INDO+UCL-
1684 (G–I) in endothelium-intact mesenteric arteries isolated from normal rats incubated without (control) or with 200 mg·ml21 BSA (BSA), 200 mg·ml21
AGE-BSA (AGE-BSA), or 200 mg·ml21 AGE-BSA plus 1 mM metformin for 3 hours. In each group of experiments, mesenteric arteries were precontracted
with 1 mM PE. (n = 6 rats, one-way ANOVA with Tukey’s post test, *P , 0.05 and **P , 0.01 vs. BSA; #P , 0.05 and ##P , 0.01 vs. AGE-BSA).
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is related to its regulation of KCa3.1 and KCa2.3 expression.
HUVECs were cultured in the medium without (control) or
with 200 mg·ml21 BSA, 200 mg·ml21 AGE-BSA, and AGE-BSA
plus a different dose of metformin (1026, 1027, 1028 M) for
48 hours to determine the change in the expression level of
KCa3.1 and KCa2.3 channels by Western blot. Incubation with
a different dose ofmetformin and 200mg·ml21 BSA for 48 hours
did not affect the protein expression of KCa3.1 and KCa2.3
channels in HUVECs, whereas treatment with 200 mg·ml21
AGE-BSA for 48 hours decreased the protein expression of
KCa3.1 andKCa2.3 by 35.52 and 49.48%, respectively (Fig. 4, A–
D; n5 5, P, 0.01 vs. BSA). Incubation with 200 mg·ml21 AGE-
BSA plus 1026, 1027, or 1028 M metformin for 48 hours
attenuated the decrease of protein level, and the difference was
significant at 1026 and 1027 M (Fig. 4, C and D; n5 5, P, 0.01
vs. AGE-BSA). These results demonstrated that metformin
restored the downregulation of IKCa and SKCa channels in-
duced by AGEs.
We also observed the effect of short-term incubation of
metformin on KCa channel expression in HUVECs. The results
showed that incubation with 200 mg·ml21 BSA, 200 mg·ml21
AGE-BSA, and metformin (1026 M) plus AGE-BSA for 3 hours
did not change the expression of either KCa3.1 or KCa2.3
channels significantly in cultured HUVECs (shown in Supple-
mental Fig. 1; n 5 5, P . 0.05 vs. control), suggesting that
regulation of KCa channel expression is not involved in the
effect of short-term incubation with AGE-BSA and metformin.
Effect of Metformin on IKCa and SKCa Currents
Inhibited by AGEs in Cultured HUVECs. We then in-
vestigated whether short-term incubation with AGE-BSA and
metformin influences KCa channel activity. Figure 5A shows
the membrane currents recorded in HUVECs with 300-ms
voltage steps to between2100 mV and160 mV from a holding
potential of270 mV (inset). The membrane current with weak
inward rectification at positive potentials was sensitive to the
inhibition by IKCa channel blocker TRAM-34 (1 mM) and SKCa
channel blocker UCL-1684 (0.1 mM) in a representative cell
incubated with 200 mg·ml21 BSA for 3 hours (Fig. 5A, upper
panel). Similar results were obtained in the other four cells.
These results suggest that both IKCa and SKCa channels are
predominantly expressed in cultured HUVECs. To determine
whether the membrane currents were affected by AGEs, the
cells were incubated with the medium containing 200 mg·ml21
AGE-BSA for 3 hours. Themembrane current was significantly
decreased in cells treatedwith AGE-BSA, and the sensitivity to
TRAM-34 (1 mM) or UCL-1684 (0.1 mM) was also weakened by
AGE-BSA (Fig. 5A, middle panel). Pretreatment with metfor-
min (1 mM) partly reversed the inhibitory effects of AGE-BSA
on the currents (Fig. 5A, lower panel). Figure 5B illustrates the
mean values of current-voltage (I-V) relationships of TRAM-
34–sensitive current obtained by digital subtraction of the
current before TRAM-34 from the current after TRAM-34
application in cells with 200 mg·ml21 BSA (control) or
200 mg·ml21 AGE-BSA and 1 mM metformin plus AGE-BSA.
The I-V curves of TRAM-34–sensitive current showed a weak
inward rectification. The current density at 260 to 160 mV
was smaller in cells treated with AGE-BSA (n5 5, P , 0.05 or
P , 0.01 vs. control). The decreased current by AGE-BSA was
partly antagonized by coincubation of metformin and AGE-
BSA (n 5 5, P , 0.05 or P , 0.01 vs. AGE-BSA alone). These
results indicate that the decrease of IKCa current by AGE-BSA
is upregulated by metformin in cultured HUVECs.
Fig. 3. Effect of metformin on IKCa- and SKCa-mediated NS309-induced relaxation in small arteries incubated with AGEs. (A–F) Cumulative
concentration-response curves for NS309 in the absence or presence of TRAM-34 (A–C) or UCL-1684 (D–F) in endothelium-intact mesenteric arteries
from normal rats incubated without (control) or with 200 mg·ml21 BSA (BSA), 200 mg·ml21 AGE-BSA (AGE-BSA), or 200 mg·ml21 AGE-BSA plus 1 mM
metformin for 3 hours. In each group of experiments, mesenteric arteries were precontracted with 1 mM PE. (n = 6 rats, one-way ANOVA with Tukey’s
post test, *P , 0.05 and **P , 0.01 vs. BSA; #P , 0.05 and ##P , 0.01 versus AGE-BSA).
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Figure 5C displays the I-V relationships of mean values of
UCL-1684–sensitive current obtained by digitally subtracting
the current before UCL-1684 from the current after UCL-
1684 application in cells with 200 mg·ml21 BSA (control) or
200 mg·ml21 AGE-BSA and metformin (1 mM) plus AGE-BSA.
The current density at 110 to 160 mV was remarkably
decreased in cells treated with AGE-BSA (n 5 5, P , 0.05 or
P , 0.01 vs. control) and almost fully restored by metformin
plus AGE-BSA (n 5 5, P , 0.05 or P , 0.01 vs. AGE-BSA
alone). These results indicate that the inhibition of SKCa
current by AGE-BSA is upregulated by metformin in cultured
HUVECs.
Involvement of ROS in the Effect of Metformin on
Regulation of KCa Channels in HUVECs. We further
explored whether intracellular ROS generation detected by
DCF-DA and DHE was influenced by metformin. Compared
with unstimulated and BSA-treated cells, ROS activity in
HUVECs treated by 200 mg·ml21 AGE-BSA for 24 hours
increased remarkably as indicated by fluorescence intensity of
both fluorescent probes (Fig. 6, A–C; n5 8, P, 0.01 vs. BSA).
Metformin (1 mM) treatment reversed this condition (Fig. 6,
A–C; n 5 8, P , 0.01 vs. AGE-BSA).
To mimic the impairment of ROS, we used 40 mM H2O2 to
treat HUVECs preincubated with or without different doses of
metformin (1026, 1027, 1028 M) for 48 hours. Incubation with
40 mMH2O2 for 48 hours reduced the expression of the KCa2.3
channel by 64.08% and expression of the KCa3.1 channel by
55.98%, respectively (Fig. 6, D and E; n 5 5, P , 0.01
vs. control). Incubation with 40 mM H2O2 plus 10
26, 1027, or
1028 M metformin for 48 hours attenuated the decreasing of
protein level, and the difference was significant at 1026 and
1027 M (Fig. 6, D and E; n 5 5, P , 0.05 or P , 0.01 vs. AGE-
BSA). These results demonstrated that metformin restored
the downregulation of IKCa and SKCa channels induced by
H2O2, which suggested that inhibiting the impairment of ROS
on HUVECs is likely related to the beneficial effect of
metformin on regulation of KCa channels.
Effect of Metformin on AMPK Activation under AGE-
Induced Pathologic Conditions. To evaluate whether the
beneficial effect of metformin on regulation of KCa channels in
HUVECs is related to the activation of the AMPK pathway,
we performed a Western blot analysis with a specific antibody
against phosphorylated Thr172 of AMPK, which is reported to
be essential for the AMPK activity, in HUVECs treated with
200 mg·ml21 BSA, 200 mg·ml21 AGE-BSA, AGE-BSA plus
1026∼1023 M metformin, 6,7-dihydro-4-hydroxy-3-(29-hydroxy
[1,19-biphenyl]-4-yl)-6-oxo-thieno[2,3-b]pyridine-5-carbonitrile
(Ab120335), or Compound C for 3 hours. As shown in Fig. 7A,
Fig. 4. Effect of metformin on downregu-
lation of KCa3.1 and KCa2.3 channels
induced by AGEs in cultured HUVECs.
(A) Representative Western blot images
and quantitative analysis of KCa3.1 chan-
nel protein levels in HUVECs treated
without (control) or with different doses
of metformin (1028∼1026 M) for 48 hours.
(B) Representative Western blot images
and quantitative analysis of KCa2.3 chan-
nel protein levels in HUVECs treated with
the interventions as described in (A). (C)
Representative Western blot images and
quantitative analysis of KCa3.1 channel
protein levels in HUVECs treated without
(control) or with 200 mg·ml21 BSA (BSA),
200 mg·ml21 AGE-BSA (AGE-BSA), and
200 mg·ml21 AGE-BSA plus different doses
of metformin (1028∼1026 M) for 48 hours.
(D) Representative Western blot images
and quantitative analysis of KCa2.3 chan-
nel protein levels in HUVECs treated with
the interventions as described in (C). (n = 5,
one-way ANOVA with Bonferroni’s post
test, **P , 0.01 vs. BSA; ##P , 0.01 vs.
AGE-BSA).
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the relative level of p-AMPK Thr172 was reduced in cells
incubated with AGE-BSA (n5 5, P, 0.05 vs. BSA), which was
antagonized by coincubation of 10 mM Ab120335, an AMPK
agonist (n 5 5, P , 0.05 vs. AGE-BSA), but not 1026 M
metformin, the dose we used in this study in vitro. Only more
than 1024 M metformin significantly reversed the decrease of
p-AMPK level by AGE-BSA (Fig. 7B; n5 5, P, 0.05, P, 0.01
vs. AGE-BSA), and the effect of 1023 M metformin was
countered by 10 mM Compound C (Fig. 7B; n 5 5, P , 0.05
vs. AGE-BSA plus 1023 M metformin), a specific AMPK
inhibitor. These results indicated that high concentrations of
metformin are required to activate AMPK under AGE-induced
pathologic conditions.
Discussion
In the present study, we found that 1) long-term treatment
with metformin improved the impairment of IKCa- and SKCa-
mediated relaxation in the third-order mesenteric arteries
from rats with STZ-induced diabetes, in which restoring IKCa
and SKCa channel expression downregulated by AGEs through
inhibiting ROS increase in endothelial cells, at least in part,
was involved; and 2) short-term treatment with metformin
reversed the damage of IKCa- and SKCa-mediated relaxation
induced by short-term AGE incubation in small mesenteric
arteries through activation of IKCa and SKCa channels without
changing the channel expression.
Metformin is one of the most commonly used therapeutic
drugs for the treatment of T2DM. It not only lowers blood
glucose concentration but also inhibits adipose tissue lipolysis,
reduces circulating levels of free fatty acids, decreases forma-
tion of AGEs, and improves insulin sensitivity (Kirpichnikov
et al., 2002). In addition, metformin improves lipid profiles
and lowers blood pressure in both patients and animals with
impaired glucose tolerance and T2DM (Verma et al., 1994;
Kirpichnikov et al., 2002). It has been shown that metformin
also has vasculoprotective effects (Katakam et al., 2000;
Mather et al., 2001; Kirpichnikov et al., 2002; Iida et al.,
Fig. 5. Effect of metformin on IKCa and SKCa currents
inhibited by AGEs in cultured HUVECs. (A) Membrane
currents recorded with the protocol as shown in the inset in
cells treated with BSA (200 mg·ml21), AGE-BSA (200 mg·ml21),
and AGE-BSA plus metformin (1 mM) for 3 hours before and
after application of TRAM-34 (1 mM) and UCL-1684 (0.1 mM).
(B) I-V relationships of the mean values of TRAM-34–sensitive
current obtained by digital subtraction of the current before
TRAM-34 from the current after TRAM-34 application (n = 5
for each groups). (C) I-V relationships of the mean values of
UCL-1684–sensitive current obtained by digital subtraction of
the current before UCL-1684 from the current after UCL-1684
application (n = 5 for each groups).
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2003), which are largely independent of its well known
antihyperglycemic action. In overweight T2DM patients,
metformin use is associated with a decrease in macrovascular
morbidity and mortality (UK Prospective Diabetes Study
(UKPDS) Group, 1998). Metformin improved the vascular
function in obese nondiabetic rats (Lobato et al., 2012) and
insulin-resistant rats (Katakam et al., 2000). In the present
study, we used STZ-treated rats with a 3-month high-fat and
high-glucose diet as an animal model of diabetes. The diabetes
model was characterized by an increase of fasting blood
glucose, serum cholesterol, glycosylated hemoglobin, blood
serum insulin, and mean artery pressure, as well as reduced
body weight, as previously described (Wang et al., 2010; Su
et al., 2011), which was similar to the state of patients with
T2DM. Our data showed that, after 3-month treatment with
metformin, the impaired ACh-induced endothelium-dependent
relaxation, especially the EDHF-type relaxation, in small
mesenteric arteries was reversed (Fig. 1, C and D), which
further confirmed its vasculoprotective effect.
Despite the large number of studies published, it remains
unclear which mechanisms underlie the vasculoprotective
actions of metformin. In resistance arteries, the contribution
of NO appears to be less important than in conduit vessels,
and EDHF appears to play a major role in regulating tissue
blood flow (Félétou and Vanhoutte, 2009). Findings from
IKCa- and/or SKCa-deficient mice indicate that endothelial
IKCa and SKCa are indeed fundamental components of the
EDHF-signaling pathway in vivo (Grgic et al., 2009). There
are reports indicating that impaired EDHF-mediated relax-
ations in small mesenteric arteries in animal models of
diabetes involve endothelial KCa channels (McPherson, 1992;
Morikawa et al., 2005). In the present study, using selective
blockers of IKCa and SKCa, TRAM-34 andUCL-1684, we found
that metformin restored the impaired ACh-induced EDHF-
mediated vasodilation which was related to its beneficial
effect on IKCa- and SKCa-mediated relaxation (Fig. 1, E–H).
AGE is one of the key pathogenic factors of diabetic vascular
complications (Yamagishi et al., 2005; Rahman et al., 2007;
Fig. 6. Involvement of ROS in the effect of
metformin on regulation of KCa channels in
HUVECs. (A) Image showing ROS gener-
ation detected by DCF-DA (green) and
DHE (red) in cultured HUVECs treated
without (control) or with 200 mg·ml21 BSA,
200 mg·ml21 AGE-BSA, or 200 mg·ml21
AGE-BSA plus 1mMmetformin for 24 hours.
Magnification = 200. (B and C) quantitative
analysis of DCF-DA (B) andDHE (C) positive
staining in HUVECs treated with the inter-
ventions as described in (A) (n = 8, one-
way ANOVA with Bonferroni’s post test,
**P, 0.01 vs. BSA; ##P, 0.01 vs. AGE-BSA).
(DandE)RepresentativeWesternblot images
and quantitative analysis of KCa3.1 channel
(D) and KCa2.3 channel (E) protein levels in
HUVECs treated without (control) or with
40mMH2O2, 40mMH2O2 plus different doses
of metformin (1028∼1026 M) for 48 hours
(n = 5, one-way ANOVA with Bonferroni’s
post test, **P , 0.01 vs. control; #P , 0.05
and ##P , 0.01 vs. H2O2).
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Gao et al., 2008; Negre-Salvayre et al., 2009). Our previous
study showed that short-term exposure to AGE-BSA impaired
EDHF-mediated relaxations in rat mesenteric arteries (Zhao
et al., 2014). In this study, we also used the same method to
mimic the direct effect of AGEs and observe the influence of
metformin on AGE-induced impairment in rat mesenteric
arteries. The results showed that direct incubation of isolated
mesenteric arteries with metformin for 3 hours significantly
reversed AGE-impaired IKCa- and SKCa-mediated ACh-
induced EDHF-type relaxation (Fig. 2). NS309 is a positive
modulator of both SKCa and IKCa channels with no effect on
big-conductance Ca21-activated potassium channels (Si et al.,
2006). In high concentrations, NS309 has been shown to
inhibit the activity of the voltage-dependent calcium channels
causing smooth muscle relaxation (Morimura et al., 2006). In
the present study, NS309 was applied to confirm the effect
of metformin on IKCa- and SKCa-mediated vasodilatation
(Fig. 3), and the maximum concentration was 1 mM, which is
well below the IC50 (10.6 6 1.1 mM) for inhibiting voltage-
dependent calcium channels previously found in tissue
preparations. We did not observe the direct effect of metformin
on vasodilation of rat mesenteric arteries. Previous dose-
response experiments have demonstrated that, in rat tail and
mesenteric arteries, metformin-induced vasodilation only
occurred at very high concentrations (.10 mM) (Chen et al.,
1997; Katakam et al., 2000).
Metformin is a guanidine compound that is structurally
related to aminoguanidine, and has been reported to have
a potential effect on the inhibition of glycation reactions
(Tanaka et al., 1997; Ruggiero-Lopez et al., 1999; Kiho et al.,
2005; Brown et al., 2006). Metformin therapy reduced the
atherogenic AGE molecules in the serum of women with
polycystic ovary syndrome (Diamanti-Kandarakis et al.,
2007). Our data showed that metformin attenuated the
increase of HbA1c in diabetic rats (Table 1), the level of which
is positively correlated with the serum level of AGEs (Jakus
et al., 2014). In vitro treatment of arterioles with 1 mM
metformin also significantly reversed the impaired IKCa- and
SKCa-mediated relaxation of isolated mesenteric arteries in-
duced by direct AGE-BSA incubation (Figs. 2 and 3), sug-
gesting that there should be other mechanisms besides its
inhibition of AGE generation. The results from our Western
blot analysis showed that 3-hour incubation with 200 mg·ml21
AGE-BSA or 1 mM metformin plus AGE-BSA did not change
the expression of either KCa3.1 or KCa2.3 channels (Supple-
mental Fig. 1). Patch voltage-clamp analysis showed that both
TRAM-34–sensitive current (IKCa channel current) and
UCL-1684–sensitive current (SKCa channel current) were
decreased by 3-hour incubation with AGE-BSA (200 mg·ml21)
and reversed by coincubation with metformin (1 mM) and
AGE-BSA (Fig. 5). These evidences suggest that the short-
term effect of AGEs and metformin on vascular relaxation is
not related to the alteration of KCa channel expression, but to
the change of channel activity. However, 48-hour incubation
with metformin reversed AGE-induced downregulation of
KCa3.1 and KCa2.3 (Fig. 4), which is in line with our previous
study (Zhao et al., 2014). These results indicated that
alterations of the KCa channel both in protein expression
and channel activity may be responsible for the beneficial
effect of metformin on IKCa- and SKCa-mediated relaxation in
vivo. However, we cannot exclude other mechanisms concern-
ing the inhibitory effect of metformin on receptor for AGEs
(RAGE) and downstream processes (Ouslimani et al., 2007;
Ishibashi et al., 2012a,b).
In endothelial cells, the interaction of AGEs with RAGE can
activate complex signaling pathways, causing increased
generation of ROS (Goldin et al., 2006). Enhanced generation
of ROS and changes in antioxidant capacity are thought to be
the etiology of chronic diabetic complications (Matheus et al.,
2013). ROS have been proposed to be regulators of K1 channel
function in various tissues (Kourie, 1998). In our previous
study, diabetic rats treated with the antioxidant alpha lipoic
acid, which can quench ROS, showed the restored IKCa- and
SKCa-mediated relaxation in mesenteric arteries (Zhao et al.,
2013). Alpha lipoic acid also attenuated AGE-induced impair-
ment of IKCa- and SKCa-mediated relaxation in mesenteric
Fig. 7. Effect ofmetformin on the p-AMPK
level under AGE-induced pathologic con-
ditions. (A) Representative Western blot
images and relative levels of p-AMPK
Thr172 (to total AMPK) in HUVECs treated
without (control) or with 200 mg·ml21 BSA,
200mg·ml21 AGE-BSA, and AGE-BSA plus
10 mM Ab120335 or 1 mM metformin for
3 hours. (B) Representative Western blot
images and relative levels of p-AMPKThr172
(to total AMPK) in HUVECs treated with
200 mg·ml21 BSA, 200 mg·ml21 AGE-BSA,
AGE-BSA plus different doses of metformin
(1025∼1023 M), or 1023 M metformin and
10 mM Compound C for 3 hours. (n = 5,
one-way ANOVA with Bonferroni’s post
test, *P, 0.05 vs. BSA; #P, 0.05, ##P, 0.01
vs.AGE-BSA;&P,0.05vs.AGE-BSA+1023M
metformin).
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arteries, and reversed AGE-induced downregulation of KCa3.1
and KCa2.3 channels in cultured HUVECs (Zhao et al., 2014).
These previous studies confirmed the harmful role of ROS in
IKCa- and SKCa-mediated relaxation. Metformin exhibits
antioxidant properties that contribute to the vascular pro-
tective effects observed in several epidemiologic studies (UK
Prospective Diabetes Study (UKPDS) Group, 1998). Treat-
ment with metformin restores endothelial function through
inhibiting endoplasmic reticulum stress and oxidative stress
in obese diabetic mice (Cheang et al., 2014). In cultured bovine
aortic endothelial cells, the intracellular antioxidant proper-
ties of metformin (10 mM) result in the inhibition of cell
expression of both RAGE and lectin-like oxidized receptor 1,
possibly through a modulation of redox-sensible nuclear
factors such as NF-kB (Ouslimani et al., 2007). Our present
data showed that metformin reversed the enhanced ROS
generation induced by AGEs (Fig. 5, A–C) and the reduced
expression of KCa3.1 and KCa2.3 by H2O2 (Fig. 6). These
evidences indicated that the effect of metformin in this study
might be related to inhibition of AGE-induced oxidation.
Several reports (Zou et al., 2004; Towler and Hardie, 2007)
have provided evidence that metformin (100 mM to 10 mM)
activates AMPK. Our results also showed that only a high
dose of metformin (.100 mM) significantly reversed the
decrease of p-AMPK level by AGE-BSA (Fig. 7), indicating
that high concentrations of metformin are required to activate
AMPK under AGE-induced pathologic conditions. Therefore,
it seems that the AMPK pathway is not involved in the
observed effects of metformin at 1 mM in this study.
In summary, the present study demonstrated that metfor-
min treatment improved the vascular function in rats with
STZ-induced diabetes by reversing AGE-induced impairment
of IKCa- and SKCa-mediated relaxation. Our findings support
the beneficial effects of metformin previously demonstrated in
large intervention studies in type 2 diabetic patients.
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